Carve-ups are the new M&A: the best buyers take the slice they can run

The deal is the slice

The week's deals have little in common by size or therapeutic area, but they share a shape. Almost none involves one company swallowing another whole. CorMedix is buying substantially all of Heron Therapeutics' assets, which is four hospital products, not the corporate shell. Charles River is taking Frontage's Exton bioanalysis and DMPK businesses for about $470m, through a consortium structure that first takes Frontage private. Ocugen has licensed its retinitis pigmentosa gene therapy only for Australia, New Zealand and ASEAN. Edesa has granted Kyorin exclusive Japanese rights to its ARDS antibody. Acrivon bought one Phase 2-ready JAK1 inhibitor and one preclinical programme.

Our view is that this modularity is a strategy, not a fallback. In each case, someone decided which piece an owner could actually run well and priced only that piece.

What a clean cut buys

Take CorMedix and Heron. The four marketed products carry about $150 million in trailing-12-month net revenue, and the upfront value is about $222.6 million. By our arithmetic that is roughly one and a half times trailing revenue, before contingent earn-outs and with the consideration split across cash and shares. A Pharmakon term loan backs the purchase. The buyer is acquiring a defined commercial footprint in postoperative pain and nausea and vomiting, not a research organisation or a balance sheet it has to rationalise.

Acrivon's purchase works the same way from the other side. It enters immunology with undisclosed cash and owes Aqilion no future royalties or milestones. A clean break leaves no tail of obligations to manage.

The licences cut the map instead of the portfolio. Edesa's Kyorin deal is worth over $140m in total but only $12m is upfront, with the rest in milestones and royalties. Ocugen's partner takes a region while Phase 3 top-line data are still expected in the first quarter of 2027. The owner keeps the rest of the world and the decision on how to use it.

The strongest counter-argument

The best objection is that slicing is what is left when whole-company deals are out of reach. Carve-outs carry their own costs. Shared systems, people and contracts have to be separated, and Charles River's route through a take-private of Frontage shows how much machinery a clean purchase can need. Piecemeal licences can also cap an owner's upside in precisely the territories where a drug later succeeds. ANI's proposed offer for Egetis, built around EMCITATE, is a reminder that whole-company bids are still being made, and that some buyers want everything.

That is fair, and it is why we are not calling the slice always superior. But the objection supports our point. Where the cut is poorly chosen, the buyer inherits stranded costs and the seller gives away value. The skill is in drawing the line, and the week's better deals show lines drawn deliberately: marketed products with measurable revenue, a defined service unit, a named geography.

Why it matters now

Closings are not here yet. CorMedix and Heron expect to complete in the first quarter of 2027, and ANI's offer has not closed. The structures will be tested in execution. Even so, the direction is clear. Small and mid-sized companies increasingly treat their assets as separable units to sell, license or buy, and the counterparty with the best understanding of its own operating limits will set the terms.